Search
Silo Pharma Inc
SILOAdd to Watchlist
6.180USD
+0.010+0.16%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
6.70MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.16%
5 Days
+2.23%
1 Month
+1.15%
6 Months
+1741.48%
Year to Date
+1717.65%
1 Year
+903.90%
Key Figures
6.170Open
6.280High
53.86KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
4.97%Turnover Ratio
6.170Prev. Close
5.890Low
195.50KTurnover
LossP/E Static
1.18P/B
0.00%Div Yield TTM
-74.99%ROA
1.21052wk High
0.84Volume Ratio
-4.39MNet Profit
1.08MShares
-0.3945EPS TTM
0.56Beta
-99.94%ROE
0.22152wk Low
6.32%Amplitude
-14.77%Gross Margin
6.70MMarket Cap
0.16Reward/Risk
6.08%Risk Rate
TradingKey Stock Score of Silo Pharma Inc
Currency: USD Updated: 2026-07-02Key Insights
Silo Pharma Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 124 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Silo Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Silo Pharma Inc Highlights
StrengthsRisks
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.10K.
Undervalued
The company’s latest PE is -15.66, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.31M shares, decreasing 32.90% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.97.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Silo Pharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Silo Pharma Inc Info
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Ticker SymbolSILO
CompanySilo Pharma Inc
CEOWeisblum (Eric)
Websitehttps://silopharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Silo Pharma Inc (SILO)?
The current price of Silo Pharma Inc (SILO) is 6.18.
What is the symbol of Silo Pharma Inc?
The ticker symbol of Silo Pharma Inc is SILO.
What is the 52-week high of Silo Pharma Inc?
The 52-week high of Silo Pharma Inc is 1.21.
What is the 52-week low of Silo Pharma Inc?
The 52-week low of Silo Pharma Inc is 0.22.
What is the market capitalization of Silo Pharma Inc?
The market capitalization of Silo Pharma Inc is 6.70M.
What is the Earnings Per Share (EPS TTM) of Silo Pharma Inc (SILO)?
The Earnings Per Share (EPS TTM) of Silo Pharma Inc (SILO) is -7.57.